Home > Journals > Minerva Ginecologica > Past Issues > Articles online first > Minerva Ginecologica 2017 Apr 10

CURRENT ISSUE
 

ARTICLE TOOLS

Reprints

MINERVA GINECOLOGICA

A Journal on Obstetrics and Gynecology


Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Scopus, Emerging Sources Citation Index


eTOC

 

Minerva Ginecologica 2017 Apr 10

DOI: 10.23736/S0026-4784.17.04067-9

Copyright © 2017 EDIZIONI MINERVA MEDICA

language: English

Gonadotropin-releasing hormone analogues for the prevention of chemotherapy-induced premature ovarian failure in breast cancer patients

Benedetta CONTE 1, Lucia DEL MASTRO 2

1 UO Oncologia Medica 2, IRCCS AOU San Martino-IST, Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy; 2 S.S. Sviluppo Terapie Innovative, IRCCS AOU San Martino-IST, Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy


PDF  


Since the survival of patients with cancer has significantly improved, chemotherapy-related premature ovarian failure (POF) in young cancer survivors has become a major issue in oncology. POF is associated with several health-related negative consequences, including menopausal symptoms, increased risk of cardiovascular diseases, osteoporosis, sexual disfunction, and infertility1-5. According to the major international guidelines, embryo/oocyte cryopreservation are the standard procedures for fertility preservation in young cancer women6,7. However, these techniques do not protect the whole ovarian function from the gonadotoxicity of anticancer therapies; indeed, they can only preserve fertility without preventing POF and related side effects. In recent years, temporary ovarian suppression during chemotherapy with lutenising hormone-releasing hormone analogues (LHRHa) has emerged as an option to preserve both gonadal function and fertility. Despite temporary ovarian suppression with LHRHa showed to be an effective strategy to reduce the risk of treatment-related POF in several randomized clinical trials, its use as a standard procedure is still under debate. The present review will encompass the current evidences and controversies on the efficacy and safety of ovarian protection with LHRHa during chemotherapy for preservation of ovarian function and fertilityin breast cancer patients, in light of the new data published.


KEY WORDS: Fertility preservation - Breast cancer - Evaluation luteinising hormone-releasing hormone analogues (LHRHa) - Premature ovarian failure

top of page

Publication History

Cite this article as

Corresponding author e-mail

lucia.delmastro@hsanmartino.it